Mishra, N
Gong J, Xu J, Zhu W et al (2010) Epithelial-specific blockade of MyD88-dependent pathway causes spontaneous small intestinal inflammation
Book a visit today and our team will help you find the right plan for your goals
Retatrutide Facts to Know Right Now As of April 9, 2026, retatrutide is still in Phase 3 trials and is not FDA-approved Lilly says it is legally available only inside Lilly clinical trials It is being studied as a once-weekly shot TRIUMPH-4 reported 28.7% average weight loss at 68 weeks on 12 mg TRANSCEND-T2D-1 reported 16.8% average weight loss at 40 weeks on 12 mg in adults with type 2 diabetes In TRIUMPH-4, tingling or burning skin was reported by 20.9% of people on 12 mg Lilly says more retatrutide results are expected over the next year The tracker basics stay simple: log the dose, mark the site, track symptoms, food, water, and weight Retatrutide may still be trial-only, but the weekly routine around it is real
No, hair loss associated with GLP-1 medications is typically temporary telogen effluvium that resolves within 6 months after weight stabilizes
